Similar risks seen for apixaban and dabigatran versus aspirin, while rates were higher for rivaroxaban<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 11, 2025 (HealthDay News) — Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are higher for rivaroxaban, according to a review published online Feb. 11 in the Annals of Internal Medicine<\/em>.<\/p>\n Michael Ke Wang, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues estimated the differences in bleeding risks between therapeutic-dose nonvitamin K oral anticoagulants (NOACs) and single antiplatelet therapy using data from nine randomized controlled trials with 26,224 participants. All of the studies used aspirin as the antiplatelet therapy.<\/p>\n The researchers found that apixaban had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.0 [95 percent confidence interval, \u22121.3 to 2.6] and \u22120.2 [95 percent confidence interval, \u22120.6 to 1.4] percentage points, respectively). Dabigatran also had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.5 [95 percent confidence interval, \u22122.1 to 19.6] and 0.0 [95 percent confidence interval, \u22121.1 to 24.5] percentage points, respectively). Rivaroxaban had higher rates of major bleeding and intracranial hemorrhage than aspirin (risk differences, 0.9 [95 percent confidence interval, \u22120.1 to 3.7] and 0.3 [95 percent confidence interval, \u22120.1 to 79.7] percentage points, respectively). The certainty of evidence varied from low to moderate.<\/p>\n “Our findings are similar to those reported by a previous network meta-analysis, which found indirect evidence that therapeutic-dose rivaroxaban had the highest risk for bleeding out of the NOACs compared with aspirin when used for extended anticoagulation in this population,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\nStay up to date on the latest in health \u2014 Click here to subscribe to our weekly newsletter!<\/a><\/strong><\/h4>\n<\/div>\n